medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2012, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2012; 28 (3)

Hematological emergencies. III. Methotrexate toxicity

Jaime-Fagundo JC, Forrellat-Barrios M, Arencibia-Núñez A

Language: Spanish
References: 24
Page: 246-252
PDF size: 150.89 Kb.


ABSTRACT

Methotrexate is an antimetabolite which competitively inhibits the dihydrofolate reductase enzyme and has anti-proliferative and immunosuppressive activity and therefore it is used in the treatment of various hematological malignancies. The main adverse effects are myelosuppression, renal insufficiency, mucositis and neurological disorders. The adequate management of intoxication by this drug is very important since fast and appropriate actions can reverse the damage and save the patient's life. A review of the behaviour against acute toxicity by this drug is reported.


REFERENCES

  1. Jukes TH. The history of methotrexate. Cutis. 1978 Mar;21(3):396-8.

  2. Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood. 1949 Feb;4(2):160-7.

  3. Zachariae H. Methotrexate side-effects. Br J Dermatol. 2006 Jun;122(36):12733.

  4. Bleyer WA. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep. 1977;61:1419-25.

  5. Relling MV, Fairclough D, Ayers D, Crom R, Rodman JH, Puig CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicicy. J Clin Oncol. 1994 Aug;12(8):1667-72.

  6. Rubnitz JE, Relling MV, Harrison PL, Sandlund JT, Ribeiro RC, Rivera GK, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia. 1998 Aug;12(8):1176-81.

  7. Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol. 1986 Dec;4(12):1845-50.

  8. Jaffe N, Takaue Y, Anzai T, Robertson R. Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer. 1985 Sep 15;56(6):1356-60.

  9. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993 Dec;92(6):2675-82.

  10. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277-84.

  11. Miller MB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan;47:207-14.

  12. Pauley JL, Panetta JC, Schmidt J, Kornegay N, Relling MV, Pui CH. Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol. 2004 Aug;54(2):146-52.

  13. Borsi JD, Sagen E, Romslo I, Moe PJ. Rescue after intermediate and high-dose methotrexate: background, rationale and current practice. Pediatr Hematol Oncol. 1990;7(4):347-63.

  14. Winick NJ, Bowman WP, Kamen BA. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst. 1992 Feb 19;84(4):252-6.

  15. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008 Mar;9(3):257-68.

  16. Boulanger H, Launay B, Vacher V, Hierniaux P, Fau JB, Deray G. Severe methotrexate intoxication in a hemodialysis patient treated for rheumatoid arthritis. Nephrol Dial Transplant. 2001 May;16(5):1087.

  17. Buchen S, Ngampolo1 D, Melton RG, Hasan C, Zoubek A, Henze G. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005 Feb 14;92(3):480-7.

  18. Estève MA, Devictor-Pierre B, Galy G, André N, Coze C, Lacarelle, et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol. 2007 Jan;63(1):39-42.

  19. Gosselin S, Isbister GK. Treatment of accidental intrathecal methotrexate overdose. J Natl Cancer Inst. 2005 Apr 20;97(8):609-10.

  20. Patterson DM, Lee SM. Glucarpidase following high-dose methotrexate: update on development. Expert Opin Biol Ther. 2010 Jan;10(1):105-11.

  21. Peris F. Estudio farmacocinético de la interacción metotrexato-colestiramina. Implicaciones terapéuticas. [Tesis doctoral] Valencia: Universidad de Valencia. Facultad de Farmacia; 1995.

  22. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2006;2. Art. No.: CD000978. DOI: 10.1002/14651858.CD000978.pub2.

  23. Sonis ST. Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid. 2010 Jun 15;4:199-205.

  24. Vizcaíno Y, Arencibia A, Londian MA, Abelardo CM, Rodeiro I. Farmacogenética aplicada al tratamiento de la leucemia linfoide aguda Rev Cubana Hematol Inmunol Hemoter [serie en Internet] 2011 Ago; 27(3) [citado 2011 Ago 26]. Disponible en: http://bvs.sld.cu/revistas/hih/vol27_3_11/hih03311.htm




2020     |     www.medigraphic.com